Apr. 22 at 6:07 PM
$MCRB
$MCRB – Recent News Summary
Seres Therapeutics continues to position SER-155 as its key value driver, with new data presented at ESCMID reinforcing its potential in reducing serious infections in high-risk patients (e.g. stem cell transplant).
* SER-155 (microbiome-based therapy) has already shown ~77% reduction in bloodstream infections in Phase 1b 
* Program is Phase 2–ready, with FDA Breakthrough & Fast Track designations 
* New data supports microbiome restoration and infection prevention (scientific validation)
Near-term catalysts:
* Q2 2026 clinical readout (immune-related enterocolitis study) 
* Potential Phase 2 launch (pending funding) 
Financial context:
* ~
$45.8M cash, runway into Q3 2026 
* Actively seeking partnerships / funding
* Cost cuts + restructuring ongoing
Takeaway:
Bullish science, but still a high-risk biotech story — upside depends on funding + next clinical data.
